Comments
Vivimed Labs gained as USFDA has given zero 483 observations after inspecting the company's API manufacturing facility in Sant Celoni, Spain.
The company shares surged as much as 6.7 per cent, its biggest intraday percentage gain in over a week.
The stock has jumped about 17 per cent this year, as of Tuesday's close.
Vivimed Laboratories had yesterday said the US health regulator had recently inspected the drug maker’s manufacturing plant in Spain and has not issued any observations.
In a notice to the exchanges, the drug firm said its active pharmaceutical ingredient manufacturing facility at Sant Celoni, Spain, was recently inspected by the USFDA. At the end of the successful inspection, ‘zero’ 483 observations were issued, it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.